Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Canagliflozin (Primary) ; Canagliflozin/teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 20 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.
- 30 Oct 2017 New trial record